What’s Going on with Agenus?
Yesterday, Sept. 16, the immuno-oncology company Agenus (AGEN) announced that it had presented final results from its Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021. The study examined Balstilimab plus zalifrelimab to treat patients with recurrent/metastatic cervical cancer. Pre-market this morning, AGEN shares were trading at $5.95, which is a 6.82% increase in value per share.
What Does This Mean for AGEN?
“With a median follow-up of almost 2 years, the Bal/Zal combination showed high response rates, durable clinical activity, and promising overall survival results,” Agenus Chief Medical Officer Steven O’Day, MD, explained.
“Furthermore,” O’Day continued, “later this year we expect to present new data on our next-generation CTLA-4 inhibitor AGEN1181, which we expect to further define the positive role this combination strategy could have in addressing unmet needs for cancer patients.”
The study recorded improved responses across all histology subgroups, including patients who were unresponsive to other therapies. 155 patients with recurrent/metastatic cervical cancer were involved in the Phase 2 trial. Dr. David O’Malley, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine, is set to deliver an oral presentation of the study data on Sept. 19 at the ESMO Virtual Conference as well.
AGEN has a Fundamental Rank of 78. Find out what this means to you and get the rest of the rankings on AGEN!
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.
